• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

VEGFR2 / Flk-1 / CD309 / KDR recombinant protein

Scan QR to view Datasheet
Catalog # MBS2546580
Unit / Price
  0.05 mg  /  $445 +1 FREE 8GB USB
  0.1 mg  /  $635 +1 FREE 8GB USB
SDS-PAGE
Product Name

VEGFR2 / Flk-1 / CD309 / KDR, Recombinant Protein

Popular Item
Also Known As

Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His tag)

Product Synonym Names
CD309, FLK1, VEGFR, VEGFR2, KDR
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
MBS2546580 Technical Datasheet
Sequence Length
1356
OMIM
EU826563 mRNA
3D Structure
ModBase 3D Structure for P35968
Host
Human Cells
Purity/Purification
> 97 % as determined by SDS-PAGE
Form/Format
Lyophilized from sterile PBS, pH 7.4, 7.5% mannitol.
Source
Human
Predicted N Terminal
Ala 20
Endotoxin
< 1.0 EU per ug of the protein as determined by the LAL method
Bio-Activity
1.- Using the Octet RED systerm, the affinity constant (Kd)of human VEGFR2-his bound to biotinylated human VEGF165 was 5.9 nM.
2.- Measured by its ability to inhibit the VEGF- dependetn profilerration of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 10-50 ug/mL in the presence of 10 ng/mL recombinant human VEGF165.
Reconstitution
It is recommended that sterile water (200 uL) be added to the vial to prepare a stock solution of 0.25 mg/mL.
Concentration is measured by UV-Vis.
Stability
Samples are stable for up to twelve months from date of receipt at -70°C .
Preparation and Storage
Store it under sterile conditions at -20°c to -80°C. It is recommended that the protein be aliquot and be used as soon as possible. Avoid repeated freeze- thaw cycles.
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of VEGFR2 / Flk-1 / CD309 / KDR recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
VEGFR2 / Flk-1 / CD309 / KDR recombinant protein
Background: VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.

Description: A DNA sequence encoding the extracellular domain of human VEGFR2 (NP_002244.1) (Met 1-Glu 764) was fused with a polyhistidine tag at the C-terminus.
The secreted recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of rhVEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions.

NCBI/Uniprot data below describe general gene information for VEGFR2 / Flk-1 / CD309 / KDR. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
vascular endothelial growth factor receptor 2
NCBI Official Synonym Full Names
kinase insert domain receptor
NCBI Official Symbol
NCBI Official Synonym Symbols
FLK1; CD309; VEGFR; VEGFR2
  [Similar Products]
NCBI Protein Information
vascular endothelial growth factor receptor 2
UniProt Protein Name
Vascular endothelial growth factor receptor 2
UniProt Synonym Protein Names
Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD_antigen: CD309
UniProt Gene Name
UniProt Synonym Gene Names
FLK1; VEGFR2; VEGFR-2; FLK-1; KDR  [Similar Products]
NCBI Summary for VEGFR2 / Flk-1 / CD309 / KDR
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]
UniProt Comments for VEGFR2 / Flk-1 / CD309 / KDR
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000